Bristol Myers, Exelixis announce Opdivo in combo with Cabometyx shows durable survival with over 3 years of follow-up in CheckMate -9ER trial in first-line advanced RCC

Prensa/medios de comunicación

Período15 feb. 2023

Cobertura de los medios

1

Cobertura de los medios

  • NombreBristol Myers, Exelixis announce Opdivo in combo with Cabometyx shows durable survival with over 3 years of follow-up in CheckMate -9ER trial in first-line advanced RCC
    Nombre/canal del medio de comunicaciónPharmaBiz
    País/TerritorioIndia
    Fecha15/02/23
    PersonasMauricio Burotto